Distant and local recurrence in patients with biochemical failure after prostate brachytherapy

Brachytherapy

Volumn 7, Issue 3, 2008, Pages 217-222

  Stock, Richard G ^a   Cesaretti, Jamie A ^a   Unger, Pamela ^a   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Patterns of failure; Prostate brachytherapy; Prostate cancer; PSA doubling time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; BIOPSY; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; TIME FACTORS; TREATMENT FAILURE;

EID: 46849095599     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.04.002     Document Type: Article

References (24)

1. Partin A.W., Pearson J.D., Landis P.K., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43 (1994) 649-659
2. D'Amico A.V., and Hanks G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72 (1993) 2638-2643
3. Pollack A., Zagars G.K., and Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74 (1994) 670-678
4. Roach III M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer; recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
5. Fleming I.D., and Cooper J.S. AJCC 1992 staging system (1997), Lippincott-Raven, Philadelphia, PA
6. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219-225
7. Stone N.N., and Stock R.G. Prostate brachytherapy: Treatment strategies. J Urol 162 (1999) 421-426
8. Lee L.N., Stock R.G., and Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 444-452
9. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
10. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
11. Petraki C.D., and Sfikas C.P. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 1 (2007) 107-118
12. Stock R.G., Stone N.N., Kao J., et al. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: Implications for treatment optimization. Cancer 89 (2000) 1829-1834
13. Norusis M.J. SPSS 10.0 guide to data analysis (2000), Prentice-Hall, Upper Saddle River, NJ
14. Pollack A., Zagars G.K., Antolak J.A., et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54 (2002) 677-685
15. Cox J.D., Gallagher M.J., Hammond E.H., et al. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17 (1999) 1155-1163
16. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
17. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
18. Wallner K., Merrick G., True L., et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
19. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
20. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
21. Laverdiere J., Gomez J.L., Suburu E.R., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
22. Stock R.G., Cesaretti J.A., and Stone N.N. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66 (2006) 389-394
23. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
24. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) 42-46